|
|
Vaccine Detail
|
VEGFR2-169 Peptide Vaccine |
| Vaccine Information |
- Vaccine Name: VEGFR2-169 Peptide Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007142
- Type: Peptide Vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Kdr
gene engineering:
- Preparation: DNA encoding murine VEGFR-2 (FLK-1) was cloned and inserted into the pcDNA3.1 vector between the restriction sites Kpn1 and Xba1 generating pcDNA3.1-FLK1(Niethammer et al., 2002). VEGFR2-expressing cells were generated by infecting the target cells with the recombinant adenoviral vector carrying VEGFR2 cDNA (Wada et al., 2005).
- Description: This is for Pancreatic Cancer (NCT00639925). A peptide vaccine containing an HLA-A*2402-restricted epitope of vascular endothelial growth factor receptor (VEGFR) 2 with potential immunostimulatory and antineoplastic activities. Upon administration, VEGFR2-169 peptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against VEGFR2-expressing tumor cells. VEGFR2, a receptor tyrosine kinase, is overexpressed by a variety of tumor types; overexpression is associated with tumor cell proliferation and tumor angiogenesis. HLA-A*2402 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*2402 may improve antigenic peptide immunogenicity (Wada et al., 2005; NCIT_C74090).
|
| Host Response |
|
|
| References |
NCIT_C74090: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C74090]
NCT00639925: [https://clinicaltrials.gov/show/NCT00639925/]
Niethammer et al., 2002: Niethammer AG, Xiang R, Becker JC, Wodrich H, Pertl U, Karsten G, Eliceiri BP, Reisfeld RA. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nature medicine. 2002; 8(12); 1369-1375. [PubMed: 12415261].
Wada et al., 2005: Wada S, Tsunoda T, Baba T, Primus FJ, Kuwano H, Shibuya M, Tahara H. Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2. Cancer research. 2005; 65(11); 4939-4946. [PubMed: 15930316].
|
|
